Antiandrogenic progestins for treatment of signs of androgenisation and hormonal contraception

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 112, Issue 2, 2004, Pages 136-141

  Schindler, Adolf E ^a  

^a Institute for Medical Research and Education Essen   (Germany)

Author keywords

Antiandrogenic progestins; Hormonal contraception; Ovarian cancer; PCOS; Signs of androgenisation

Indexed keywords

CHLORMADINONE ACETATE; CYPROTERONE ACETATE; DIENOGEST; DROSPIRENONE; ETHINYLESTRADIOL; GESTAGEN;

ACNE; ALOPECIA; ANEMIA; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; DYSMENORRHEA; ENDOMETRIUM CANCER; HIRSUTISM; HORMONAL CONTRACEPTION; HUMAN; LIPID METABOLISM; MENSTRUAL CYCLE; OVARY CANCER; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; REVIEW; SEBORRHEA; VIRILIZATION;

EID: 1642463939     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2003.09.030     Document Type: Review

References (24)

1. James VHT, Goodall A. Androgen production in women. In: Jeffcoate SL, editor. Androgen- and antiandrogen therapy. Lancaster: Wiley, 1982. p. 23-40.
2. Muhn P., Krattenmacher R., Beier S., Elger W., Schillinger E. Drospirenone: another progestogen with antimineralocorticoid and antiandrogenic activity. Contraception. 51:1995;99-110.
3. Schindler AE. Antiandrogen estrogens therapy for signs of androgenisation. New developments in biosciences, vol. 3. Berlin: Walther de Gruyter, 1987.
4. Loch EG, Schramm G. Chlormadinonacetat bei Androgenisierungserscheinungen. Stuttgart: Schattauer, 1995.
5. Golbs S., Nikolov R., Zimmermann T. Pharmacology of nortestosterone derivatives. Menopause Rev. VI:2001;29-44.
6. Kuhl H. Neue Gestagene- ihre Vor- und Nachteile. Therap. Rundschau. 58:2001;527-533.
7. Aydinlik S., Kaufmann J., Lachnit-Fixson U., Lehnert J. Long-term therapy of signs of androgenisation with low-dosed antiandrogen-estrogen combination. Clin. Trial J. 27:1990;392-402.
8. Gollwick H., Albring M., Brill K. The efficacy of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type. J. Dermatol. Treatment. 9:1998;71-79.
9. Falsetti L., Gambera A., Tisi G. Efficacy of the combination ethinylestradiol and cyproterone acetate in endocrine, clinical and ultrasonic profile in polycystic ovary syndrome. Hum. Reprod. 16:2001;36-42.
10. Ashton RE, Miller JA, Wojnarowska FT, Dowd PM, O'Brian TJ, Griffiths WAD, Jacobs HS. Antiandrogen treatment in women with acne: a controlled trial. In: Schindler AE, editor. Antiandrogen-estrogen therapy for signs of androgenization. New developments in biosciences, vol. 3. Berlin: Walther de Gruyter, 1987. p. 117-30.
11. Dramusic V., Goh V.H., Rajan U., Wong Y.C., Ratnam S.S. Clinical, endocrinologic, and ultrasonographic features of polycystic ovary syndrome in Singaporean adolescents. J. Pediatr. Adolesc. Gynecol. 10:1997;125-132.
12. ® ). Results of a marketing surveillance study Clin. Drug Invest. 22:2002;221-231.
13. ® on skin and hair. Results of a post-marketing surveillance study. Drugs Today. 35(Suppl. C):1999;97-104.
14. Bokisch E., Skarabis H., Wuttke W., Heidegger R. The acceptability of a novel oral contraceptive containing drospirenone and its effects on well-being. Eur. J. Contracept. Reprod. Health Care. 5(Suppl. 3):2000;34-40.
15. Drife JO. The benefits and risks of oral contraceptives today. 2nd ed. Carnforth (UK): Parthenon Publishing, 1996. p. 23.
16. Venturoli S., Paradisi R., Saviotti E., Porcu E., Fabbri R., Orsini L.F.et al. Ultrasound study of ovarian and uterine morphology in women with PCOS before, during and after treatment with CPA and EE. Arch. Gynecol. 237:1987;1-10.
17. Schindler A.E., Mangold K., Friedrich E., Keller E., Göser R. Therapy of androgenic symtomatology with cyproterone acetate and ethinylestradiol. Arch. Gynäk. 225:1978;103-107.
18. Zaradnik HP, Moore C. Clinical experience with an oral contraceptive containing ethinylestradiol dienogest. In: Elstein M, editor. Extragenital effects of oral contraceptives. Lancaster: Parthenon, 1997. p. 53-61.
19. ® on skin and hair: a postmarketing surveillance study. Int. J. Clin. Pract. 54:2000;85-91.
20. Huber J., Foidart J.M., Wuttke W. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur. J. Contracept. Reprod. Health Care. 5(Suppl. 3):2000;25-34.
21. Moltz L. Differenzierter Einsatz von Cyproteronazetat bei verschiedenen androgenbedingten Krankheitsbildern der Frau. In: Breckwoldt M, editor. Diagnostik und Therapie von Androgenisierungserscheinungen bei der Frau. Berlin: Diesbach, 1992. p. 154-61.
22. Godsland IF, Stevenson JC. Postmenopausal hormone replacement therapy and insulin metabolism: effects of route of administration and implication for heart disease and diabetes risk. Br J Clin Pract 1998;86, Suppl:1-5.
23. Rosano GMC, Vitale C, Silvestre A, Fini M. Metabolic and vascular effect of progestins in postmenopausal women. Implication for cardioprotection. Maturitas, in press.
24. Van Vloten W.A., van Haselen C.W., van Zuuren E.J., Gerlinger C., Heithecker R. The effect of two combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 69(4):2002;2-14.